The Veeda Clinical Research Limited Date Will Be Updated Soon .
Veeda Clinical Research Limited, formed in 1989, is a non-bank financial institution that specializes in providing loan funding to underprivileged families and businesses.
Start your investing journey today. How do you open your own demat account for free?
Bidding Dates
Coming Soon
Price Range
₹0 per share
Face Value
₹0 per share
GMP
₹0
Veeda Clinical Research Limited GMP
The Veeda Clinical Research Limited IPO GMP is ₹[].
IPO Overview
Veeda Clinical Research Ltd, a company focusing on bioavailability and bioequivalence studies, filed its draft red herring prospectus (DRHP) in September 2021. SEBI has already given its observations and approval for the IPO in December 2021.
Usually, the IPOs are approved by SEBI within 2 to 3 months unless there are other queries or clarifications that the regulator has. The IPO of Veeda Clinical Research Ltd will be a combination of a fresh issue and an offer for sale, but the next step will be for the company to finalize its issue date and price to start the IPO process.
Veeda Clinical Research Limited IPO Financials
| Particulars (in Rs. Crores) | FY21 | FY20 | FY19 |
| Revenue | 19.58 | 15.13 | 21.84 |
| EBITDA | 6.67 | 1.94 | 8.82 |
| PAT | 6.33 | 0.0 | 4.42 |
| EPS (basic in Rs.) | 15.39 | -0.01 | 12.17 |
| ROE | 37.16% | -0.05% | 50.20% |
| ROCE | 26.72% | 3.42% | 75.94% |
| Cash generated from operating activities | 7.66 | 0.91 | 8.20 |
| Net cash from investing activities | -9.26 | -0.90 | -0.93 |
| Net cash flow from financing activities | 1.71 | -0.34 | -6.14 |
| Net increase in cash and cash equivalents | 0.11 | -0.33 | 1.13 |
Company Profile
Veeda Clinical Research Limited serves clients in North America, Europe, and Asia, covering most of the medication development and launch value chain. Bioanalytical services, such as bioavailability and bioequivalence (“BA and BE”) investigations, are provided, as is a comprehensive suite of clinical trials, including pre-clinical, early-phase, and late-phase clinical trials and ancillary services. They had grown from a single facility in Ahmedabad with a total capacity of 62 beds and a monthly capacity of 7,000 samples to four facilities in Ahmedabad and one in Mehsana with a total capacity of 532 beds and a monthly capacity of 100,000 samples as of March 31, 2021.
They presently have pre-clinical trial capabilities with two facilities in Bangalore, each with 99 separate experiment rooms and self-contained chemistry, biopharmaceutical, and analytical laboratories. They have conducted pharmacokinetic (“PK“) investigations as well as generic, new chemical entities (“NCEs“), giant molecules, and biosimilar trials.
IPO Strenghts
- Experienced promoters and a competent management team.
- Well-established relationships with a loyal customer base.
- Access to markets worldwide, enabling global reach.
IPO Weakness
- Heavy reliance on customers based in the United States.
- Need to adhere to multiple laws and regulations in these countries to ensure compliance.
- Competition from other players in the market.
